ArticleMolecular neurobiology2026
Neuroprotective Effect of Chitosan Nanoparticle-Delivered Orientin Against Hypoxia-Induced Brain Injury in Rats.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chitosan-Orientin Nanoparticles Attenuate Hypoxia-Induced Pulmonary Inflammation in Rats.Biomolecules · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reduced brain oxygenation rapidly amplifies oxidative and inflammatory injury, creating a self-perpetuating cascade that can end in neuronal loss. Orientin can activate Nrf2/ARE-dependent antioxidant responses and suppress NF-κB-mediated inflammation, but poor solubility and limited bioavailability weaken its therapeutic impact. Here, we used chitosan nanoparticles (CNPs) to improve Orientin delivery and evaluated the protective effects of CNPs/Orientin on oxidative stress, inflammation, and apoptosis in hypoxia-induced brain injury. Forty-eight male Wistar albino rats were split into eight groups: (Control, Orientin, CNPs, CNPs/Orientin, Hypoxia, Hypoxia+Orientin, Hypoxia+CNPs, Hypoxia+CNPs/Orientin). The hypoxia model was applied with an 8% O₂+92% N₂ gas mixture for 8 h per day for 7 days. Orientin (40 mg/kg/day, i.p.) was administered simultaneously with the hypoxia period. MDA, SOD, GSH, BDNF, HIF-1α, iNOS, IL-1β, and TNF-α levels were determined by ELISA; gene expressions of Caspase-3, Bcl-2, HO-1, NRF2, NF-κB, and TNF-α were quantified by RT-PCR. Histological evaluations were performed in the cortex and hippocampus regions. CNPs/Orientin had a mean diameter of ~245 nm, a positive zeta potential (+29 mV), 81.3% encapsulation efficiency, and sustained release (79.6% over 72 h). Hypoxia significantly decreased SOD, GSH, and BDNF, while increasing MDA, HIF-1α, iNOS, and Caspase-3 levels (p < 0.05). All treatment groups attenuated the hypoxia-induced increase in IL-1β and TNF-α; however, cytokine levels did not differ significantly among the treatment arms. In the Hypoxia+CNPs/Orientin group, oxidative/nitrosative markers and neuronal histopathological findings were improved compared with hypoxia. Orientin delivered via chitosan nanoparticles demonstrated a significant neuroprotective effect, reducing oxidative stress, inflammation, and apoptosis while preserving neuronal structural integrity in hypoxia-induced brain injury. These results suggest that the nano-carrier form of Orientin may be a potential therapeutic agent in neurodegenerative processes.
Indexed as
Identifiers
42521892What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.